Department of Clinical Immunology, Shanghai Renji Hospital Shanghai Second Medical University, Shanghai 200001, China;
Department of Clinical Immunology, Shanghai Renji Hospital Shanghai Second Medical University, Shanghai 200001, China;
Department of Clinical Immunology, Shanghai Renji Hospital Shanghai Second Medical University, Shanghai 200001, China;
Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai 200000, China;
Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai 200000, China;
Department of Rheumatology, Shanghai Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China;
Department of Clinical Immunology, Affiliated Hospital of Anhui Medical University, Hefei 230022, China;
Department of Rheumatology, Anhui Provincial Hospital, Hefei 230001, China;
Department of Rheumatology, Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;
Department of Rheumatology, Nanjing Gulou Hospital, Nanjing 210008, China;
Department of Rheumatology, Tongji Hospital Tongji Medical University, Wuhan 430003, China;
Department of Rheumatology, Beijing Friendship Hospital, Beijing 100050, China;
Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230022, China;
Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230022, China;
leflunomide; rheumatoid arthritis; methotrexate; clinical trial;